We determined the presence of extended-spectrum-␤-lactamase (ESBL)-producing Escherichia coli among 3,344 study participants from the German community. Intestinal colonization was detected in 211 persons (6.3%), without significant differences among the different age groups. The majority (95.2%) of isolates harbored CTX-M-type ESBL, with CTX-M-15 (46%) and CTX-M-1 (24.2%) as the most common types. The finding of ESBL producers and one isolate additionally producing carbapenemase OXA-244 indicates a risk of dissemination of resistant bacteria outside the hospitals.
mid-mediated ampC genes (bla ACC , bla CMY , bla DHA , bla FOX , bla MOX ) was performed for all isolates with reduced susceptibility or resistance to cefoxitin (zone diameter of Ͻ19 mm), and isolates with reduced susceptibility or resistance to ertapenem (zone diameter of Ͻ25 mm) or imipenem or meropenem (zone diameter of Ͻ22 mm) were tested for the presence of carbapenemase genes bla KPC-type , bla OXA-48-type , bla NDM-type , bla GIM-type , bla IMP-type , and bla VIM-type , as described recently (12, 13) . Additionally, isolates with reduced susceptibility or resistance to nalidixic acid (zone diameter of Ͻ19 mm) and/or ciprofloxacin (zone diameter of Ͻ22 mm) were screened for the presence of the plasmid-mediated quinolone resistance (PMQR) genes aac(6=)-Ib-cr, qnrA/B/C/D/S, and qepA (14) . Furthermore, basic typing of E. coli isolates was performed by determination of the four E. coli phylogenetic groups using a PCR-based assay (15) .
The results showed the presence of cefotaxime-resistant E. coli in 213 of 3,344 fecal samples (6.4%). Phenotypic ESBL production was confirmed in 211 of 213 isolates. Therefore, the rate of fecal carriage of ESBL-producing E. coli in the study population was 6.3%. This rate is in accordance with data recently reported in France (6.0%) (9), Switzerland (5.8%) (16), Japan (6.4%) (17) , and Tunisia (7.3%) (7) and considerably lower than those reported in other world regions, such as China (50%) (18) , Egypt (63%) (19) , and Thailand (65.7%) (8) . Furthermore, no significant difference of ESBL carriage was observed related to the different age groups or gender in the present study (P Ͼ 0.05; chisquare test using SPSS, version 21.0).
Apart from cefotaxime resistance, the 211 ESBL-positive E. coli isolates were additionally resistant to further antibiotics, e.g., 1.4% (n ϭ 3) of all ESBL-producing E. coli isolates were resistant to ertapenem, 51.6% (n ϭ 109) to nalidixic acid, 36.0% (n ϭ 76) to ciprofloxacin, 28.9% (n ϭ 61) to gentamicin, 55.9% (n ϭ 118) to trimethoprim-sulfamethoxazole, and 62.1% (n ϭ 131) to tet-racycline. Interestingly, 23 isolates (10.9%) were simultaneously resistant to nalidixic acid, ciprofloxacin, tetracycline, trimethoprim-sulfamethoxazole, and gentamicin.
Using PCR and sequencing, we found that 201 (95.2%) of all ESBL-producing E. coli isolates harbored bla CTX-M-type genes ( Table 1 ). The two remaining cefotaxime-resistant E. coli isolates without the ESBL phenotype were positive for AmpC ␤-lactamases of type CMY-2. The most common ESBL types in this study were CTX-M-15 (46.0%), CTX-M-1 (24.2%), and CTX-M-14 (14.7%), as reported previously in other countries (9, 16) . Remarkably, one ertapenem-resistant isolate (zone diameter of Ͻ15 mm) expressed both a CTX-M-14 ESBL and the carbapenemase OXA-244. OXA-244 is closely related to the worldwide prevalent OXA-48 carbapenemase and was first described in 2013 in Klebsiella pneumoniae from a Spanish hospital (20) . In contrast, six further E. coli isolates of this study with reduced susceptibility (n ϭ 4) or resistance (n ϭ 2) to ertapenem did not harbor carbapenemase genes, indicating the presence of other mechanisms of resistance, e.g., reduced membrane permeability due to loss of porins (21) . Furthermore, we found PMQR genes in 40 (33.9%) of 118 ESBL-producing E. coli isolates with reduced susceptibility or resistance to nalidixic acid and/or ciprofloxacin (Table 1) . Recent studies from Japan and Korea showed similar prevalences of transferable resistance mechanisms to quinolones in ESBL producers (22, 23) .
Bacterial typing revealed that the majority of all ESBL-producing isolates belonged to the phylogenetic groups A (40.3%) and D (38.4%). Similar ratios of phylogenetic groups were also observed when considering only E. coli isolates expressing either CTX-M-15, CTX-M-14, or CTX-M-1 (Table 1) . These results were to be expected for E. coli isolates from the community since previous phylogenetic analyses have shown that commensal strains of E. coli more often belong to group A, while virulent extraintestinal strains causing nosocomial infections belong mainly to group B2 (15) .
In conclusion, our results suggest that the fecal carriage of ESBL-producing E. coli occurs in the German community at high rates independently of age and gender. The study included 3,344 participants from the general population that had contact with patients with gastroenteritis. Since further epidemiological data of the study participants (e.g., other diseases, previous antibiotic treatment, and previous stay abroad/in hospital) were not available, we cannot exclude that at least some of the identified ESBLproducing E. coli infections could have been acquired in hospitals. Moreover, as the patients with gastroenteritis were not screened for ESBL-producing E. coli, we cannot exclude a possible transmission of these resistant bacteria from the patients to the contact persons. However, the occurrence of these different ESBL-and even carbapenemase-producing E. coli strains as colonizers in the community indicates a reservoir outside the hospitals that should be taken seriously regarding implementation of screening and hygiene precautions for prevention of infections with these drugresistant bacteria.
